Leukemia & Lymphoma最新文献_第2页

Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma. epcoritamab CD20靶向t细胞接合剂和CD20抗体靶向治疗b细胞非霍奇金淋巴瘤的联合治疗。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-18 DOI: 10.1080/10428194.2025.2504719

Durga B Dandamudi, Iwona M Konieczna, Kelly M Calabrese, Monica Wielgos-Bonvallet, Christiaan Kweekel, Elke Gresnigt-van den Heuvel, Ramesh Iyer, Paul Ellis, Luis Rodriguez, Apurvasena Parikh, Tommy Li, Madelon Paauwe, Cormac Cosgrove, Adam S Chervin, Edward B Reilly, Pearlie Epling-Burnette, Edith Szafer-Glusman

{"title":"Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma.","authors":"Durga B Dandamudi, Iwona M Konieczna, Kelly M Calabrese, Monica Wielgos-Bonvallet, Christiaan Kweekel, Elke Gresnigt-van den Heuvel, Ramesh Iyer, Paul Ellis, Luis Rodriguez, Apurvasena Parikh, Tommy Li, Madelon Paauwe, Cormac Cosgrove, Adam S Chervin, Edward B Reilly, Pearlie Epling-Burnette, Edith Szafer-Glusman","doi":"10.1080/10428194.2025.2504719","DOIUrl":"https://doi.org/10.1080/10428194.2025.2504719","url":null,"abstract":"Epcoritamab, a subcutaneous CD3xCD20 bispecific antibody approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, is being evaluated in regimens containing CD20-targeted monoclonal antibodies (e.g. rituximab plus cylophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]). To demonstrate combinability of epcoritamab with CD20 monoclonal antibodies (mAbs), potential interference of rituximab or obinutuzumab with epcoritamab was investigated. While there was dose-dependent binding interference between CD20 mAbs and epcoritamab through steric hindrance, ex vivo assays using tumor cell lines, R-CHOP-treated patient samples, and an animal model showed this did not impair tumor cell killing. In a pharmacokinetic model, >90% maximal cytotoxicity was predicted after the first full epcoritamab dose in the presence of therapeutic rituximab concentrations due to effective tumor-epcoritamab-T-cell trimer formation. Immunoprofiling of R-CHOP-treated DLBCL patient samples showed emergence of less-differentiated CD8 memory T cells, further supporting the feasibility of the combination in ongoing studies of epcoritamab with rituximab-containing chemoimmunotherapy.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lower-dose venetoclax (LoVe) based regimes in children with acute leukemia. 急性白血病儿童低剂量venetoclax （LoVe）治疗方案

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-18 DOI: 10.1080/10428194.2025.2519920

Bhuvanesh Narayan Purohit, Vivek Mohan, Varun Capoor, Sachin Jain, Rahul Naithani

引用次数: 0

Real-world healthcare costs for patients treated with chimeric antigen receptor T-cell therapy in Canada. 在加拿大，使用嵌合抗原受体t细胞治疗的患者的实际医疗保健费用。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-17 DOI: 10.1080/10428194.2025.2518440

Lisa Masucci, John Kuruvilla, Beate Sander, Anca Prica, William W L Wong, Kelvin K W Chan

引用次数: 0

Acalabrutinib resistance in a CLL patient harboring a C515 mutation in the BTK-C isoform. BTK-C异构体C515突变的CLL患者的阿卡拉布替尼耐药性

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-16 DOI: 10.1080/10428194.2025.2518434

Maria Dimou, Maria Karypidou, Aikaterini Bitsani, Marina Belia, Anastasia Kopsaftopoulou, Kalliopi Zerzi, Andreas Kyriakopoulos, Sotirios Sachanas, Ilias Pessach, Aikaterini Kolotsiou, Maria K Angelopoulou, Marina Siakantaris, Theodoros P Vassilakopoulos, Panayiotis Panayiotidis

引用次数: 0

Familial aspects of multiple myeloma and Waldenström macroglobulinemia: understanding the predisposition in relatives and the importance of early diagnosis. 多发性骨髓瘤和Waldenström巨球蛋白血症的家族性：了解亲属的易感性和早期诊断的重要性。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-13 DOI: 10.1080/10428194.2025.2516256

Neta Sternbach, Morie A Gertz

引用次数: 0

Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control arm. olutasidenib与ivosidenib在复发或对venetoclax难治的异柠檬酸脱氢酶1突变急性髓系白血病患者中的有效性：2102-HEM-101试验与基于美国电子健康记录的外部对照组

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-13 DOI: 10.1080/10428194.2025.2514894

Catherine E Lai, Thomas P Leahy, Alex J Turner, Amber Thomassen, Lixia Wang, Aaron D Sheppard, Jorge Cortes

{"title":"Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control arm.","authors":"Catherine E Lai, Thomas P Leahy, Alex J Turner, Amber Thomassen, Lixia Wang, Aaron D Sheppard, Jorge Cortes","doi":"10.1080/10428194.2025.2514894","DOIUrl":"https://doi.org/10.1080/10428194.2025.2514894","url":null,"abstract":"First-line venetoclax (VEN) treatment for acute myeloid leukemia (AML) has high relapse rates, with limited evidence guiding subsequent therapy sequencing. This study evaluated the effectiveness of olutasidenib (OLU) versus ivosidenib (IVO) for patients withIDH1 relapsed/refractory (R/R) AML previously treated with VEN based therapy. Outcomes were compared between a subcohort of OLU-treated patients from the 2102-HEM-101 trial and an external control arm of IVO-treated patients from the Loopback Analytics electronic health record database. Entropy balancing was applied to align key prognostic variables. Risk differences (RD) for response/TI were estimated via logistic regression, and hazard ratios (HR) for OS via Cox regression. Following weighting, treatment with OLU versus IVO was associated with significantly higher rates of complete response (RD: 0.25; 95%CI: 0.01, 0.49), transfusion independence (RD: 0.27; 95%CI: 0.01, 0.53), and OS (HR: 0.33; 95%CI: 0.11, 0.94). Results suggest favorable effectiveness of OLU versus IVO in this population.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144285138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials. 抗cd38单克隆抗体在新诊断多发性骨髓瘤患者中的疗效和安全性：基于随机对照试验的最新系统评价和荟萃分析

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-12 DOI: 10.1080/10428194.2025.2512031

Zujie Lin, Ruijun Dong, Wenxiang Zhang, Rui Liu, Bingjie Fu, Aili He

{"title":"Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials.","authors":"Zujie Lin, Ruijun Dong, Wenxiang Zhang, Rui Liu, Bingjie Fu, Aili He","doi":"10.1080/10428194.2025.2512031","DOIUrl":"https://doi.org/10.1080/10428194.2025.2512031","url":null,"abstract":"This meta-analysis of eight phase 3 rcts assessed efficacy and safety of anti-cd38 monoclonal antibodies (mabs) in patients with newly diagnosed multiple myeloma (ndmm). anti-cd38 mabs significantly improved progression-free survival (pfs: HR 0.50, 95% CI 0.42-0.59) and overall survival (OS: HR 0.63, 95% CI 0.55-0.71) in the overall population, alongside enhanced minimal residual disease (MRD) negativity rates (RR 1.85, 95% CI 1.43-2.39). While PFS benefits were universal across subgroups, OS showed no improvement in high-risk, ISS-I, or hepatic impairment subgroups, and non-IgG subtypes lacked MRD benefit. Safety analyses demonstrated an elevated risk of multiple infection-related adverse events in the entire cohort. The risk of second primary malignancies (SPMs) also increased (RR 1.44, 95% CI 1.14-1.81). Although anti-CD38 mAbs enhance treatment efficacy with manageable toxicity, the absence of OS benefit in high-risk subgroups warrants attention, and the risk of SPMs needs further investigation.Prospero registration number: CRD42024599221.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Resistance to BTK inhibitors in leukemia: cysteine 481 in BTK equals cysteine 515 in the BTK isomer BTK-C. 白血病患者对BTK抑制剂的耐药性：BTK中的半胱氨酸481等于BTK异构体BTK- c中的半胱氨酸515。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-12 DOI: 10.1080/10428194.2025.2518433

C I Edvard Smith

引用次数: 0

CAR-T cell-associated neurotoxicity during therapy of hematologic malignancies: incidence, clinical features, predictive biomarkers and management measures. 恶性血液病治疗期间CAR-T细胞相关的神经毒性：发病率、临床特征、预测性生物标志物和管理措施

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-11 DOI: 10.1080/10428194.2025.2502810

R Velasco, I Abad-Inchaurrondo, A Sureda

{"title":"CAR-T cell-associated neurotoxicity during therapy of hematologic malignancies: incidence, clinical features, predictive biomarkers and management measures.","authors":"R Velasco, I Abad-Inchaurrondo, A Sureda","doi":"10.1080/10428194.2025.2502810","DOIUrl":"https://doi.org/10.1080/10428194.2025.2502810","url":null,"abstract":"Chimeric antigen receptor T-cell therapy (CAR-T cell therapy)-associated neurotoxicity includes a range of neurological side effects following CAR-T cell infusion. While ICANS is already a well-recognized, widely described neurological complication, the spectrum of neurological toxicities associated with CAR-T cell therapy has widened to include other, less common but emerging neurotoxicity syndromes. These have been observed with its broader use and the development of new agents. Movement and neurocognitive toxicity represent a recently described and challenging syndrome associated with BCMA-directed CAR-T cell therapies. Cranial and peripheral neuropathies, as well as myelopathy have increasingly been identified. Rare forms of cerebellar toxicity have been described with under development agents as well. Furthermore, strokes or tumor inflammation-associated syndrome (TIAN) in patients with CNS disease may elicit an emergency consultation. Finally, classical forms of acute toxic leukoencephalopathy have been described in a few patients receiving fludarabine as lymphodepleting treatment before CAR-T cell infusion. These forms of neurotoxicity vary in severity, with some cases being severe and even life-threatening in the context of CAR-T cell therapy. The present review summarizes several types of neurotoxicity associated with CAR-T cell therapy in patients with hematologic malignancies, focusing on available data on incidence, clinical presentation, prediction, diagnostics and therapeutic management.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-13"},"PeriodicalIF":2.2,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Progression of disease within 6 months: revised early disease progression threshold for ENKTL. 6个月内疾病进展：修订ENKTL的早期疾病进展阈值。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-11 DOI: 10.1080/10428194.2025.2516257

Miao Zhong, Hailing Liu, Renfu Gui, Jing Zhang, Sanmei Wang, Yi Miao, Chongyang Ding, Lvwen Chen, Yuxiao Zhao, Xiran Wang, Xiaoyan Qu, Zhengxu Sun, Ran Li, Jianyong Li, Lei Cao, Lei Fan

{"title":"Progression of disease within 6 months: revised early disease progression threshold for ENKTL.","authors":"Miao Zhong, Hailing Liu, Renfu Gui, Jing Zhang, Sanmei Wang, Yi Miao, Chongyang Ding, Lvwen Chen, Yuxiao Zhao, Xiran Wang, Xiaoyan Qu, Zhengxu Sun, Ran Li, Jianyong Li, Lei Cao, Lei Fan","doi":"10.1080/10428194.2025.2516257","DOIUrl":"https://doi.org/10.1080/10428194.2025.2516257","url":null,"abstract":"The progression of disease (POD) within 24 months is well-established as an early indicator in various lymphomas. However, the aggressive nature of extranodal NK/T-cell lymphoma (ENKTL) necessitates a shorter assessment period. In this study, we examined POD metrics in 170 newly diagnosed ENKTL patients receiving asparaginase-based regimens. Patients were divided into three groups based on relapse/progression timing: aggressive group (POD6), progressive group (POD6-24), and stable group (POD > 24). The median overall survival (OS) in the POD6 group was 16.5 months, while the median OS was not reached in the remaining two groups. Survival outcomes were comparable between the populations with POD6 and POD24. Cox regression analysis identified POD6 as an independent risk factor for OS, regardless of traditional risk stratification. In conclusion, POD6 is a valuable early prognostic marker for ENKTL, serving as a long-term prognosis surrogate for clinical studies.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0